The question is whether that activity converts into orders quickly enough. 4basebio ended 2025 with £17.8 million of cash and has since drawn a further €7 million under an existingDebtfacility, which the board says funds the group into late 2027. At 475p on 2 …
Full-year results are due this month, and the central question is whether the slippage in 340B and enterprise contract revenue is a timing problem, as management insists, or a sign of a tougher market.
That gap frames the question ahead of full results in early October: has Abingdon quietly turned the corner, with a contracted pipeline supporting what management calls "significant revenue growth" in FY27, or does growth remain hostage to the timing of individual customer programmes?
The question for investors is whether aBusinesswith no revenue, a 2025 loss of £1.9m and aMarket Valueof roughly £8.9m is being priced as a differentiated drug-delivery platform or simply as another cash-hungry small-cap. The coming months, culminating in treatment of the first patient, will …
The question for AIM investors is whether the group can convert that stability into sustained profit while extracting value from the structural heartBusinessit spun out in May 2026 and a French urogynaecology unit bought for a nominal sum. At roughly £16m of market value, …
With the new board's first full-year results due within weeks, the question for investors in this £2.3m market-cap company is whether sharper commercial focus can turn a growing order book into a business that stops burning cash.
The question for 2026 is whether aBusinesswith no revenue, £2.5m of cash at its last balance-sheet date and aMarket Valueof around £31m can convert a clean Phase 1 dataset into a licensing deal before its cash runs short. That tension is what makes SAR …
The question now is whether that momentum has carried into the current year. At its AGM on 23 July, the board said it was "encouraged" by early trading and promised a half-year update in early September. For a small-cap that rarely makes headlines, that …
The reason is not hard to find. On 4 August 2026 the group cut full-yearRevenuegrowth guidance to around 4% from around 6%, and a fortnight later said chief financial officer John Rogers would leave at the end of September. The question is whether the …
The question for anyone eyeing BSFA as a potential sleeper is whether these deals can turn aBusinesswith £18,785 of half-yearRevenueand £60,174 of cash at 31 March 2026 into a self-funding enterprise before dilution does more damage. The FY25 accounts carried a material uncertainty over …